Barbour, William
Wolff, Erika
Puar, Pankaj
Hibino, Makoto
Bakbak, Ehab
Krishnaraj, Aishwarya
Verma, Raj
Verma, Meena
Quan, Adrian
Yan, Andrew T.
Connelly, Kim A.
Teoh, Hwee
Mazer, C. David
Verma, Subodh
Funding for this research was provided by:
Boehringer Ingleheim
Article History
Received: 3 May 2023
Accepted: 6 October 2023
First Online: 15 November 2023
Declarations
:
: The EMPA-HEART CardioLink-6 randomised clinical trial study was conducted in accordance with the Declaration of Helsinki; the study design and protocol were reviewed and approved by the St. Michael’s Hospital Research Ethics Board prior to study initiation. Written informed consent was provided by all participants prior to study entry.
: Not applicable.
: KAC reports receiving research grants (to his institution), consultancy, and/or speaking honoraria from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novartis, Novo Nordisk, Sanofi, and Servier; he is listed as an inventor on a patent application by Boehringer Ingelheim for the use of DPP-4 inhibitors in heart failure. HT reports personal fees from the Canadian Medical and Surgical Knowledge Translation Research Group. CDM reports advisory board honoraria/consulting fees from Amgen, AstraZeneca, BioAge, Boehringer Ingelheim and PhaseBio and DSMB stipends from Beth Israel Deaconess Medical Center, Cerus and Takeda. SV reports receiving research grants and/or speaking honoraria from Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Canadian Medical and Surgical Knowledge Translation Research Group, Eli Lilly, HLS Therapeutics, Janssen, Novartis, Novo Nordisk, Pfizer, PhaseBio, S&L Solutions Event Management Inc, and Sanofi. SV is the President of the Canadian Medical and Surgical Knowledge Translation Research Group, a federally incorporated not-for-profit physician organization. All other authors have no relevant conflicts of interest to declare.